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The understanding of the molecular genetics in sensorineural hearing loss (SNHL) has advanced rapidly during the last decade,
but the molecular etiology of hearing impairment in the Portuguese population has not been investigated thoroughly. To provide
appropriate genetic testing and counseling to families, we analyzed the whole mitochondrial genome in 95 unrelated children
with SNHL (53 nonsyndromic and 42 syndromic) and searched for variations in two frequent genes, GJB2 and GJB6, in the non-
syndromic patients. Mutations in mtDNA were detected in 4.2% of the cases, including a hitherto undescribed change in the
mtDNA-tRNATrp gene (namely, m.5558A>G). We also identified mono- or biallelic GJB2 mutations in 20 of 53 non-syndromic
cases and also detected two novel mutations (p.P70R and p.R127QfsX84). Our data further reinforce the notion that genetic
heterogeneity is paramount in children with SNHL.
1. Introduction
Sensorineural hearing loss (SNHL) is one of the most
common disabilities in human, and genetics is an important
aspect in research and clinical practice for SNHL. One in
1000 children is born with bilateral SNHL, and 50–70%
of them have monogenic causes for their deafness [1]. In
addition, 10% of the people over 65 years have SNHL that
limits considerably speech communication. Although the
etiology is polygenic in most of the cases, with different con-
tribution of ageing and environment, discoveringmonogenic
causes has important clinical implications in terms of better
counseling and management.
Hereditary hearing loss can be classified into syndromic
and nonsyndromic depending on the associated features.
Whilst over 400 genetic syndromes have been described
in association with mono- or bilateral deafness, syndromic
conditions account for about 30% of hereditary congenital
hearing loss, whereas the relative contribution to all deaf peo-
ple is much higher (>70%) for nonsyndromic subtypes [1].
Nonsyndromic sensorineural hearing loss (NSSNHL) is
predominantly inherited in an autosomal recessive patterns
(DFNB loci) (80%) but can be also autosomal dominantly
(DFNA) (15–20%), X-linked (DFN) (2-3%), or maternally
(1%) transmitted. A polygenic or multifactorial pattern of
inheritance should be postulated for late onset cases of
hearing impairment [2, 3]. To date, 134 deafness loci (77
DFNB and 57 DFNA) have been reported, with more than 40
genes cloned [4]. Further heterogeneity is, however, expected
to emerge.
Mutations in the GJB2 and GJB6 genes on the DFNB1
locus at chromosome 13q11-q12 are responsible for up to
50% of autosomal recessive (AR) NSSNHL [5, 6]. GJB2
and GJB6 encode gap junction proteins connexin 26 (Cx26)
and connexin 30 (Cx30), respectively, which are expressed
in the cochlea where they colocalize, form heteromeric gap
junctions [7], and play a role in cochlear homeostasis [8].
The list of allelic variants in GJB2 is wide with more than 100
variants being detected, mainly in congenital AR deafness,
but also in dominant forms. The deletion of a single guanine
(c.35delG) individually account for up to 50% of cases of
NSSNHL among populations in Europe, North America,
and Asia [9, 10]. The common 342-Kb genomic deletion
in GJB6 (termed GJB6-D13S1830) occurs in up to 20% of
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the hearing-impaired American population andmay account
for ∼10% of all DFNB1 alleles with an extremely wide range
based on ethnic origin, oftentimes in dysgenic association
with the c.35delG/GJB2 variant [11, 12].
Maternally inherited hearing loss account for approx-
imately 1% of cases, but accurate diagnosis is important
because of its unique implications for affected individuals
and their family members. Hearing loss may be an early
manifestation of a more complex mitochondrial disorder
such as the Kearns-Sayre (KSS) [13–15], the MERRF
(myoclonic epilepsy with ragged-red fibers) [16, 17], or the
MELAS (mitochondrial encephalomyopathy, lactic acidosis,
and stroke-like episodes) [18, 19] syndromes. In addition,
SNHL can be the main, or sole, presenting feature of a
mtDNA defect. In particular, mutations in the mtDNA-
encoded 12S rRNA and tRNASer(UCN) genes are frequent. The
m.1555A>G mutation in 12S rRNA has a worldwide distri-
bution, and it is localized in a highly conserved region which
is involved in decoding small ribosomal subunit [20]. The
new G–C pair in 12S rRNA created by the A>G transition
facilitates the binding of aminoglycosides antibiotics such
as gentamycin and streptomycin, causing aminoglycoside-
induced NSSNHL or worsening hearing loss in individuals
harboring this mutation. The prevalence of the m.1555A>G
mutation has been shown to be between 20–30% in deaf
individuals in Spain and Asia of which 15% of them
had the history of aminoglycoside ototoxicity [21]. Addi-
tional mutations in 12S rRNA (m.961delT, m.961insC(n),
m.1005T>C, m.1095T>C, and m.1494 C>T) have been
associated with impaired hearing [22–25], although their
pathogenic significance remains controversial. All this infor-
mation indicates that the mitochondrial 12S rRNA gene is
a hotspot for mutations causing nonsyndromic hearing loss
as well as increased sensitivity to aminoglycoside ototoxicity
[26]. Mutations in the tRNASer(UCN) gene are additional
genetic hotspot in Caucasian and Asian pedigrees with
nonsyndromic and aminoglycoside-induced hearing loss. In
the vast majority of patients, mtDNA mutations are nearly
homoplasmic, indicating the requirement of a high mutation
load to exert cochlear dysfunction [27].
We performed a comprehensive analysis of GJB2 and
GJB6 in 53 non-syndromic patients and scanned the whole
mitochondrial genome formutations in a cohort of 95 paedi-
atric Portuguese SNHL patients recruited in a hearing clinic
to investigate the relative contribution of common genetic
etiologies to their disorder, provide effective assessment of
genetic risk, and to better counsel their relatives.
2. Patients andMethods
2.1. Subjects. Ninety-five Portuguese SNHL children from
unrelated families were included in this study. A diagnosis of
hearing deficit was performed in a Hearing Clinic according
to international guidelines [28]. Fifty-three cases (56%)
showed a non-syndromic hearing loss, profound in 80% and
mild to moderate in 20%, and 42 (44%) patients had a
syndromic disorder. Frequent accompanying manifestations
involved the nervous system, eye, external ear, and muscu-
loskeletal system. Parents were interviewed with regard to
age of onset, family history, mother’s health during pre-
gnancy, and patient’s past clinical history, including infec-
tion, possible head or brain injury, and the use of aminogly-
coside antibiotics. Written informed consent was obtained
from all patients or their parents prior to blood sampling
and all clinical and molecular studies accomplished with the
ethical issues of Declaration of Helsinki.
2.2. DNA Extraction. Total genomic DNA was extracted
from peripheral blood (B) or skeletal muscle (M) using
commercially available procedures which employed the EZ1
DNA Blood 350 µL Kit (QIAGEN) and Puregene Tissue kit
(Gentra) kits, respectively.
2.3. Mutational Analyses. We performed polymerase chain
reaction (PCR) amplifications and direct gene sequencing of
the coding exon and flanking regions of GJB2 in 53 non-
syndromic patients, as described elsewhere [5]. The common
GJB6-D13S1830 deletion [29] was searched in patients
harbouring a heterozygous sequence variation inGJB2. All 95
patients were screened for mutations in the entire mtDNA by
using a commercially available kit, mitoSEQr Resequencing
System for the Human Mitochondrial Genome (Applied
Biosystems, Foster City, Calif), according to the procedure
recommended by the manufacturer.
For the description of the mutations, we used the latest
conventions of the Human Genome Variation Society no-
menclature. Synonymous, missense, and splice site varia-
tions were systematically evaluated for modifications of
exonic splicing enhancers (Polyphen analysis, http://genetics
.bwh.harvard.edu/pph/; ESEfinder, http://rulai.cshl.edu/cgi-
http://rulai.cshl.edu/cgi-bin/tools/ESE/esefinder.cgi) or con-
sensus splicing sequences in order to determine the splice
site score (http://www.cbs.dtu.dk/services/NetGene2/ and
http://www.fruitfly.org/seq tools/splice.html). Multiple align-
ments with GJB2 orthologs were performed using ClustalW
(http://www.ebi.ac.uk/ Tools/msa/clustalw2/) to evaluate the
degree of conservation of missense variants. MtDNA muta-
tions and polymorphisms were searched in MITOMAP
data base (http://mitomap.org/MITOMAP).
3. Results
Table 1 summarizes molecular data detected in children
with SNHL. Sequence analysis of GJB2 indicated that eight
patients carried two mutated alleles with already described
pathogenic mutations and one presented the p.M34T muta-
tion in heterozogosity, which has been reported to cause AD-
NSSNHL [30]. The frequent c.35delG was homozygous in
four children and was detected on a single allele in eight
patients, three of whom harbored a wild-type sequence on
the other allele and two children harbored the heterozy-
gous common (GJB6-D13S1830) deletion. Two additional
patients presented novel variations in GJB2: a homozygous
p.R127QfsX84 mutation was found in one case whereas
another patient presented the p.P70R on a single allele. Four
patients presented with heteroplasmic (two individuals) or
homoplasmic (two cases) mutations in mtDNA, including
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Table 1: Genotype of patients with mutations in nuclear genes (GJB2 and GJB6) and in mitochondrial genome.
Number of patients GJB2 Reference GJB6 Reference mtDNA Reference
4 c.35delG/c.35delG [9] — —
1 p.W24X/p.W24X [30] — —
1 c.35delG/p.E47X [9, 31] — —
1 c.35delG/p.L76P [9, 32] — —
1 c.35delG/p.V95M [9, 33] — —
1 p.M34T/wt [30] — —
1 p.R127QfsX84/p.R127QfsX84 This study — —
3 c.35delG/wt [9] — —
1 p.P70R/wt This study — —
2 c.35delG [9] del(GJB6-D13S1830) [29] —
1 — — m.7445A>G [34]
1 — — m.1555A>G [20]
1 — — m.3243 A>G [19]
1 — — m.5558 A>G This study
the hitherto unreportedm.5558A>G in themtDNA-encoded
tRNATrp gene.
Collectively, about 17% (16/95) of the Portuguese
children analyzed in the present study were molecularly
characterized, whereas a single variant was identified in
four patients. The c.35delG accounted for 40% (16/40) of
all mutant alleles, and up to half of mutations occurring
in connexin-related genes. Additionally, 4.2% of stud-
ied patients (4/95) presented mutations in mtDNA, two
of them (m.5558A>G and m.7445A>G) were identified
in non-syndromic patients and the remaining mutations
(m.1555A>G and m.3243A>G) in syndromic cases.
4. Discussion
Despite increasing evidence of mutations associated with
SNHL, there have been thus far no studies reporting on
the relative frequency of mutations in the hearing-impaired
Portuguese pediatric population. Although limited to a
single center and to a relatively small number of cases, our
study demonstrated that screening of two common etiologies
(GJB2 and GJB6) can characterize one in five patients with
NSSNHL of unknown etiology. The relative frequency of
the recurrent c.35delG mutation—64% of all mutated GJB2
alleles—is in agreement with data reported by others [9, 10],
as well as, the whole mtDNA in all SNHL patients.
In the present investigation, mutations in the GJB2 gene
were very frequent among NSSNHL patients, accounted for
23.6% (25/106) of mutated alleles and appear particularly
frequent in South European patients [9, 10]. Among the
DFNB-causing GJB2 gene mutations reported so far, the
c.35delG mutation accounts for most of mutant alleles (60–
85%) in Caucasians, from which 10–50% was present in only
one allele. Our data confirms the presence of the common
GJB6-D13S1830 deletion in two patients, showing a digenic
inheritance in keeping with the severity of their hearing
deficit.
We also identified two possibly pathogenic novel vari-
ants in GJB2. The new p.P70R that substitutes a proline
(iminoacid) at codon 70 to an arginine (basic aminoacid)
was predicted to be probably damaging by PolyPhen (The
score is 2.108), and arginine was not tolerated when analyzed
with the prediction software SIFT. Whether the mutation
results in NSSNHL inherited in a dominant fashion remains
a possibility. Conversely, the novel p.R127QfsX84 predicts a
frameshift with a shorter, prematurely truncated connexin-
26.
We also detected four mutations in mtDNA, correspond-
ing to 4.2% of the all cohort. The m.1555A>G mutation
has been reported in families whose members presented
with aminoglycoside-induced deafness as the sole pathologic
feature, but it may cause hearing loss even without aminogly-
coside exposure, as in our case, which represents∼1% of this
cohort. In our study, this mutation was found in a patient
with ataxia and failure to thrive. The m.3243A>G mutation
determines not only nonsyndromic, but also syndromic
SNHL, such as in MELAS and MIDD (maternally inherited
diabetes and deafness) [1]. The case identified in the present
work was a 12-year-old boy diagnosed at the age of 8
years with syndromic SNHL; he developed hypertrophic
cardiomyopathy and generalized muscle atrophy four years
later. The m.7445A>G mutation was detected in a 13-year-
old boy who presented a history of moderate progressive
hearing loss. This mutation is believed to have led to failure
in the processing of the L-strand RNA precursor, thereby
reducing the steady-state levels of tRNASer(UCN) and ND6
mRNA [27].
We also found a novel mutation (m.5558A>G) in the
tRNATrp in a 10-year-old boy with NSSNHL. The mutation
affects the conserved A49 nucleotide in the T-stem of
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Figure 1: Schematic secondary structure of the wild-type human
mitochondrial tRNATrp gene showing the reported variants found
in this gene. Black stands for pathogenic mutations, gray stands
for polymorphic mutations, and red stands for the novel mutation
described in our study.
the tRNA (Figure 1) leading to a possible disruption of its
secondary structure after the loss of the T-stem. This modifi-
cation could also affect the tertiary structure of the tRNATrp
and has probably a consequence on the aminoacylation.
Another mutation (m.5559A>G) has been reported in the
T-stem of the tRNATrp [35], and two additional tRNATrp
mutations (namely, m.5540A>G andm.5568A>G) have been
associated with SNHL [36, 37].
5. Conclusions
Although the contribution of less common genes remains
to be determined, our results suggest that analysis of the
GJB2 gene may have clinical implications in the diagnosis
of deaf Portuguese children. Also, it would make feasible
early rehabilitation and prevention in affected families. The
relatively higher incidence of mtDNA mutation also suggests
that screening for variations in the mitochondrial genome
should always be considered unless mitochondrial inheri-
tance can be excluded for certain. The molecular diagnosis
will permit more accurate genetic counseling for family
members, monitor possible multisystem complications, and
avoid usage of aminoglycosides if infections occur.
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